Study D6582C00001 is a phase IIa randomised, double blind placebo controlled, parallel arm study to evaluate the efficacy and safety of AZD4831 in adult participants with moderate to severe chronic obstructive pulmonary disease.~Approximately 101 sites globally will participate in this study. Approximately 288 participants will be randomised to two treatment groups (AZD4831 vs placebo) in a 1:1 ratio.
This is a research study to evaluate the efficacy and safety of the investigational drug AZD4831 in adult participants with chronic obstructive pulmonary disease.